In December 2019, a novel coronavirus (COVID-19) was reported in Wuhan, a city of 11 million people in central China. The initial cases were connected to exposures in a seafood market in Wuhan [1]. As of March 23 (11.00 AM), 2020, the WHO reported 294110 confirmed cases and 12944 confirmed deaths in 187 countries of the whole world. The infected people were experienced respiratory illness and coughs. Therefore, pathogen was soon identified as a COVID-19 which is closely related to sever acute respiratory syndrome CoV (SARS-CoV).

References

1. Wu Zunyou and Jennifer M McGoogan. "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. Journal of the American Medical Association (2020).
2. Wang Manli., et al. "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research3 (2020): 269-271.
3. Lim Jaegyun., et al. "Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR”. Journal of Korean Medical Science6 (2020): e79.
4. Gao Jianjun., et al. "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-73.

Citation

Citation: Suresh Ghotekar., et al. “An Overview on Novel Coronavirus (COVID-19)". Acta Scientific Pharmaceutical Sciences 4.6 (2020): 03-05.

Copyright

Copyright: © 2020 Suresh Ghotekar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.